Fathom Therapeutics Raises $47M to Advance AI and Physics-Based Drug Discovery for Complex Biology
Capital is flowing into complexity again, and Fathom Therapeutics just secured $47M Series A to prove that hard science still gets paid when it shows receipts. Formerly Atommap Corp., now operating under a name that actually matches its depth, the New York and Boston based company is operating in territory most teams avoid because it does not forgive shortcuts. Quantum chemistry, physics based simulation, AI. Not a stack you fake your way through. Sutter Hill Ventures led the round, with Chemistry, Alexandria Venture Investments, and NY Ventures aligning behind a very specific thesis.
Follow the thread and it gets sharper. Huafeng Xu, PhD, CEO, Yujie Wu, PhD, CTO, and Jesus Izaguirre, PhD, Chief Computational Scientist are not newcomers experimenting with ideas. This is Anton supercomputer DNA showing up in a commercial form. The kind of foundation where protein motion is not approximated, it is mapped. They are taking years of computational muscle and pointing it directly at biology’s blind spots. Then you bring in Mandana Honu, PhD, CBO, a signal that business infrastructure is catching up to scientific velocity, and layer Diala Ezzeddine, ScD, MBA onto the board, and the shape of the company starts to come into focus.
Microcosmos is where the narrative shifts from impressive to consequential. Proteins are not statues, they move, they breathe, they misbehave. Fathom Therapeutics is modeling that motion at atomic resolution and pairing it with systems that understand consequences inside living cells. They report up to 10,000x acceleration in modeling protein dynamics without cutting corners on accuracy. That compresses timelines in a way the industry has been chasing for decades. Weeks instead of long, expensive cycles just to get to a viable candidate.
There is already a lead program in animal efficacy studies and multiple discovery partnerships in motion, even if the counterparties stay unnamed. That kind of silence usually means progress. The team’s prior track record includes advancing 19 drugs into the clinic, with 7 reaching FDA approval. Not a promise of what might happen, but evidence of what has already been done when this level of expertise is applied correctly.
What matters here is not just the $47M, it is what it validates. Investors are not just funding an idea, they are underwriting a shift toward physics grounded, computation heavy drug design that treats complexity as an input, not a constraint. Fathom Therapeutics is leaning into the parts of biology most models avoid, and turning them into something measurable, testable, and eventually, actionable.
